Prostate Cancer - Results from #220

Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer. September 30, 2024

Preclinical and clinical evidence for using perinatal tissue allografts in nerve sparing robot assisted radical prostatectomy to hasten recovery of functional outcomes: a literature review. September 30, 2024

Results after Four Years of Screening for Prostate Cancer with PSA and MRI. September 29, 2024

Sociodemographic disparities in prostate cancer imaging. September 27, 2024

Body composition in recurrent prostate cancer and the role of steroidogenic genotype. September 27, 2024

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer. September 27, 2024

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection. September 27, 2024

DNA Methylation-Derived Immune Cell Proportions and Cancer Risk in Black Participants. September 27, 2024

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer September 26, 2024

Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. September 26, 2024

A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer. September 26, 2024

Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-based Auto Segmentation in Pencil Beam Scanning Proton Therapy: Prostate oAPT in PBSPT. September 26, 2024

Prognostic significance of the PI-RADS score in men with prostate cancer undergoing radical prostatectomy. September 26, 2024

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival. September 26, 2024

Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope? September 25, 2024

Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial. September 25, 2024

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. September 25, 2024

Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer. September 25, 2024

Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. September 25, 2024

Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval. September 25, 2024

Page 12 of 1437